Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II RESIST study of MAP-4343 begins in patients with drug-resistant depression

Oct. 14, 2019

Libella Gene Therapeutics initiates phase I study of its AAV-hTERT gene therapy

Oct. 14, 2019

Enrollment begins in first-in-human study of REGN-5459

Oct. 14, 2019

Metformin rejuvenates stem cells, restores CNS remyelination

Oct. 14, 2019

Aruna Bio receives support for preclinical development of AB-126

Oct. 11, 2019

PanOptica reports phase I/II topline data on PAN-90806 for wet AMD

Oct. 11, 2019

Aerpio releases phase Ib interim data on topical ocular formulation of AKB-9778

Oct. 11, 2019

OSE Immunotherapeutics' bispecific anti-PD-1/IL-7 fusion molecule tested in vitro and in vivo

Oct. 11, 2019

Kangpu completes first-in-human study of KPG-818

Oct. 11, 2019

MGB Biopharma completes first cohort in phase IIa study of MGB-BP-3 in CDAD

Oct. 11, 2019

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...